Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock

This article was originally published in The Pink Sheet Daily

Executive Summary

Policy shifts to address opioid abuse epidemic include changes to immediate-release opioid labeling, updated REMS requirements, and a new advisory committee.

You may also be interested in...



A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened

Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.

Final Generic Abuse-Deterrent Opioids Guidance Coming This Year

US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.

Final Generic Abuse-Deterrent Opioids Guidance Coming This Year

US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel